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Nine-year-old Kyra, a Rhodesian ridgeback, was diagnosed with canine lymphoma after her owner noticed a
large lump on the back of her left leg.After 20 weeks of chemotherapy at the Matthew J. RyanVeterinary
Hospital, the dog’s cancer went into remission. Kyra then became the first dog to participate in a clinical trial
at Ryan—funded by the Alliance for Cancer Gene Therapy—that is testing a vaccine to sustain the remis-
sion. “We can get very valuable information about whether this is a very feasible strategy to vaccinate
humans, specifically kids with cancer,” said Dr. Karin Sorenmo, one of the trial’s principal investigators,
and chief of Ryan’s Oncology Section.
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“F
inding a cure for cancer” and “putting a
man on the moon” are phrases that con-
vey achievement of seemingly impossible
tasks: if we can put a man on the moon,
then, well, we should be able to do just
about anything.We got to the moon in 1969, but still are
searching for the cure (more likely, cures) for cancer—a
landmark in human progress that will change the world
even more than did Apollo 11. But research underway at
PennVet and elsewhere indicates we need not probe the
cosmos for this particular milestone—in fact, we may not
have to look any farther than our own feet in an easy chair
or at the end of the bed. Dogs and cats with cancer may
lead to a cure in people, and a branch of medicine called
comparative oncology may be the vehicle to get there.
Of the approximately 65 million dogs and 32 million
cats in the United States, the National Cancer Institute
estimates that each year roughly six million dogs and about
the same number of cats will be diagnosed with cancers
that share many features with human malignancies—
including osteosarcoma, prostate and breast cancers, non-
Hodgkin’s lymphoma, melanoma, soft-tissue sarcoma and
doggingcancer
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head and neck carcinoma.The sheer numbers of these
cases and the many biological similarities between people
and dogs make the latter especially ideal models for study-
ing comparable human cancers.
Also, because animals age more quickly than people and
have shorter lifespans, data from studies of new therapy
methods and drugs are obtained more quickly when
working with animals—knowledge that can be applied
that much sooner to human treatments.And one hand (or
paw) washes the other when results of large-scale research
efforts for humans can also be administered to animals.
Veterinary and medical oncologists, the pharmaceutical
industry and academic research centers are all studying
comparative oncology, the study of naturally occurring
cancers in animals as models for human disease. Many
areas of research offer promise: anti-cancer vaccines, bio-
engineering for new delivery systems, early detection.
ClinicalTrials: A Critical Component
The University of Pennsylvania School of Veterinary
Medicine is uniquely positioned to be a pioneer
in comparative oncology.As one of the only vet
schools closely integrated with a medical school,
collaboration among researchers and clinicians from
diverse backgrounds and interests is stronger than at other
universities.
Clinical trials involving animals with spontaneous dis-
ease are perhaps the most important component of com-
parative oncology studies.Although considered “experi-
mental,” treatments used in clinical trials have been previ-
ously evaluated in laboratory animals, and their safety has
been demonstrated in normal dogs and cats.The hope is
that these new approaches will significantly benefit the
patients receiving them or produce new knowledge for
others with the same condition. In fact, many effective
treatments are available today because of lab research and
patient participation in clinical trials.
“Another Perspective”
Funded by the Alliance for Cancer Gene Therapy, an
ongoing clinical trial that marks a joint effort of PennVet,
Abramson Family Cancer Research Institute and
Children’s Hospital of Philadelphia involves dogs with
lymphoma, an aggressive disease of malignant lymph
glands and/or cells. Because canine lymphoma is a sys-
temic disease—comparable to non-Hodgkin’s lymphoma
in people—chemotherapy usually is the recommended
course of treatment. Seventy to 80 percent of dogs
respond to chemotherapy at first, but the majority relapses,
and the new tumors eventually become resistant to treat-
ment. On average, survival time is one year.
The trial’s principal investigators are Dr. Karin
Sorenmo, chief of the RyanVeterinary Hospital’s
Oncology Section and associate professor of oncology;
Dr. Nicola Mason, assistant professor of immunology,
and Pamela Cole Chair in Companion Animal Medicine
at PennVet; and the Abramson Institute’s Dr. Robert
Vonderheide, assistant professor of medicine. Its purpose is
to assess the potential benefits and side effects of a novel
type of immunotherapy (a cancer vaccine) used after
remission is achieved with standard chemotherapy.The
vaccine is designed to stimulate the immune system to
recognize and attack the cancer anywhere in the body, pre-
venting relapse of the original malignancy.With this,
researchers hope to prolong the time during which the
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Cytology from a needle aspiration biopsy of a lymph node of a dog
with lymphoma.The predominant cells are lymphoblasts. Slide was
stained with a modifiedWright’s stain. / Joel Mills, DVM.
Oncology staff prepare to administer
chemotherapy treatment to Kyra.
patient is disease-free, increase the percentage of long-term
lymphoma survivors and facilitate further development of
this vaccine strategy in children patients.
“It brings another perspective to the practice of oncol-
ogy,” said Dr. Sorenmo, referring not just this study, but to
veterinary clinical trials generally,“and it’s exciting to be
part of something that reaches beyond treating dogs and
cats, even though I think that is worthy in and of itself.We
are not merely a means for researchers to figure out how
to treat humans with cancer, but treatment of animals
themselves is worthy as well.”
Ryan’s Oncology Section is also a member of the
National Cancer Institute’s Comparative Oncology Trial
Consortium (COTC), a new-drug development consor-
tium based on collaborative relationships with accredited
schools of veterinary medicine throughout the country.As
part of the COTC, PennVet was involved in another,
recently closed trial for dogs with various non-operative
malignant tumors that were treated with “tumor necrosis
factor” (TNF), a cytokine naturally produced in response
to infection, inflammatory conditions and tumors.
“The purpose of this trial in to see if it’s still safe when
we give it multiple times, but also to determine if it results
in shrinkage of the tumor,” Dr. Sorenmo explained.“I think
that the decision to take this to human clinical trials will be
very much dependent on the results of this dog trial.”
OtherTrials
Down another third-floor corridor of the RyanVeterinary
Hospital, faculty from various sections and services (prin-
cipal investigators:Dr. Deanna Worley, surgery resident,
and Dr. John Lewis,V’97, assistant professor of dentistry
and oral surgery; co-investigators:Dr. Alexander Reiter,
assistant professor in dentistry and oral surgery; Dr.
David Holt, section chief and professor of surgery;Dr.
Stanley Blazejewski,V’80, dentistry and oral surgery
resident;Dr. Dorothy Cimino Brown, assistant profes-
sor of surgery;Dr. Carrie Tupper,V’03, oncology resi-
dent; Dr.Tiffany Scanlon,V’01, pathobiology lecturer;
and Dr.TomVan Winkle, professor of veterinary pathol-
ogy and chief of the Small Animal Necropsy Service) are
involved in a clinical trial using procedures commonly
performed in human oncology to evaluate lymph-node
drainage patterns in dogs with oral malignant melanoma,
the most common malignant oral tumor in dogs (funded
by the Barry and Savannah French-Poodle Memorial
Fund and by Penn’sVeterinary Clinical Investigations
Center). Doctors combine surgical removal of regional
lymph nodes with injection of a dye to identify the sen-
tinel lymph node, which is the first node or nodes receiv-
ing drainage from a tumor.
To perform a sentinel lymph node biopsy, surgeons first
inject blue dye near the tumor several minutes before the
actual biopsy.Then, during the biopsy, surgeons inspect the
lymph nodes for staining. One or several nodes may take
the dye, and these are designated the sentinel lymph
nodes, which are then removed. Surgical excision of the
primary site of oral malignant melanoma occurs after
removal of the nodes.This method has been used in
human medicine to better determine drainage patterns
and extent of disease.
Another clinical trial involves staff from several Ryan
departments collaborating with the Lankenau Institute for
Medical Research (principal investigator:Dr. Lewis; co-
investigators:Dr. Reiter;Dr. Sorenmo;Dr. Erica
Krick,V’02, oncology lecturer;Dr.Tiffany Scanlon,
V’01, pathobiology lecturer; and Dr. Fran Shofer, epi-
demiologist statistician).This time, the team is studying the
use of a new chemotherapy drug in cats with inoperable
oral squamous cell carcinoma (SCC) (squamous cells are in
the skin’s outer layer and cover some mucosal surfaces).
Every week, the RyanVeterinary Hospital sees cases of
feline SCC, the most common oral cancer affecting cats,
accounting for up to 80 percent of all feline oral tumors.
An aggressive malignancy, it is uniformly fatal as the
tumor invades local structures of the mouth, causing pain,
lack of appetite and weight loss. Conventional treatment
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From left to right: back row: Dr. Karin Sorenmo, Dr. Robert
Vonderheide and AngharadWaite; middle row: Roxanne Bachman,
CVT, Dr. Nicola Mason and Dr. Beth Overley; front, kneeling: Michael
Wexler and Amy LaBlanc,CVT; dog: Kyra Eisenhower.
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Basic Science. Basic cancer research focuses on increasing
understanding of mechanisms that control cell reproduction,
for example, studying normal and diseased blood cells.This
scanning electron microscope image from the National
Cancer Institute shows normal circulating human blood.
Preclinical Research.During preclinical drug development,
scientists evaluate the toxic and pharmacologic effects of the
drug or treatment through in vitro and in vivo laboratory
animal testing.
Veterinary ClinicalTrials. Veterinary clinical trials involving
pets with spontaneous disease often are part of developing
new medications, procedures or therapies.
Human ClinicalTrials.Often conducted in four phases,
clinical trials involving people are conducted with volunteer
patients, usually to evaluate a new treatment, under strictly
controlled conditions. Each trial is designed to answer
scientific questions and to find better ways to treat individuals
with specific diseases.
Veterinary Application. Successful outcomes from clinical
trials are made available to veterinarians for treating pets, and
therapies from human medicine can be applied to veterinary
medicine.
HumanApplication. Successful outcomes from clinical trials
are made available to physicians for treating people, and therapies
from veterinary medicine can be applied to human medicine.
The Cycle of Translational Medicine
Basic Science
Basic Science
Clinical Application
(human and veterinary)
ClinicalTrials
(human and veterinary)
Preclinical Research
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(surgery, radiation and chemotherapy) have been of
limited benefit to most cats with large SCC tumors.
Recent research in mice, however, has proved highly
promising.Administering an enzyme-inhibiting substance
called 2-DiFluoroMethylOrnithine (DFMO) to SCC-
bearing mice produced very positive results, and even
apparent cures in a high percentage of them.Although
DFMO has not yet been used in cats, safety, toxicity pro-
files and drug dosages higher than those in the current
study have been well documented in other species. Penn
Vet clinicians are using gradually increasing doses of
DFMO to determine if the drug is well tolerated and
effective in cats (three cats are treated at an assigned dose
rate, and the next three cats are treated at a higher dose if
the previous dosage was well tolerated).
Basic Research:
The Foundation of Discovery
Before clinical oncology trials can even be considered,
however, scientists often spend years performing
basic, or “bench,” research in the laboratory, studying
communication between and workings of cells, and how
their functions are affected by different conditions and
drugs. Clinical trials—often divided into several phases
themselves—follow lengthy preclinical research in which
new drugs may be tested on laboratory animals to indicate
the maximum doses, toxicities and anti-cancer potential. It
is basic research, however, that provides the broad base of
knowledge that has and will continue to make
breakthroughs possible. X-rays, penicillin, the polio
vaccine and genetic engineering are just a few of the
numerous examples of celebrated medical advances that
evolved from preliminary basic research.
Because cancer is a disease of the cell, basic cancer
research has focused on increasing understanding of
mechanisms that control cell reproduction. But cancer
research also involves larger and smaller processes than the
cell.To learn how tumors grow and spread, researchers must
know how cells interact—and to identify and classify anti-
cancer drugs, they need a thorough knowledge of
fundamental chemistry and the newest approaches to
designing and combining drugs. In oncology, basic research
has focused on expanding knowledge of the molecular
biology of both normal and malignant cellular growth and
regulation. Given the complexity of cancer, successfully
combating it requires interaction among scientists
investigating cancer at all levels.
Some of the basic comparative oncology research
currently underway at PennVet includes ways to target
blood vessels that feed tumor cells, proteins that regulate
the ability of cells to move, and the signaling of cells in
inflammation and cancer. [See www.vet.upenn.edu/
bellwether for details.]
Banking on a Cure
At the intersection of basic and clinical research is the
School’s new Tumor Tissue Bank (TTB), housing tissue
specimens from clinical trial participants and other patients
from the RyanVeterinary Hospital.The TTB will serve
basic scientists in a wide range of research applications—
from genomics and proteomics to creating vaccines for
cancers—and will act as a repository of canine and feline
primary tumor tissue and related biofluids, like serum and
plasma. It will be linked to a searchable database that will
form the basis of a university core facility aimed at provid-
ing resources for basic and translational comparative
oncology research.
“We already have a number of samples and have
developed stable cell lines of low passage number from
them,” said Dr. Mason, who will direct the TTB with
Dr. Sam Long, assistant professor of neurology and
neurosurgery.
Historically, lack of access to tumor tissue has been a
bottleneck for cancer research. PennVet’s TTB will pro-
vide a comprehensive collection of cancer specimens with
related clinical information that will enable researchers to
address unanswered questions concerning the prognosis
and treatment of cancer.As a multi-user resource, the TTB
will be available to a wide range of cancer researchers at
Penn and elsewhere.
“Researchers at Penn’s veterinary and medical schools
are already using some of the developed lines to investi-
gate roles of certain signaling pathways in tumor develop-
ment and to assess levels of expression of tumor antigens
that may be targeted using novel immunotherapeutic
approaches,” stated Dr. Mason.“Work with these samples
will lead to a greater understanding of cancer biology and
allow great strides to be made in the field of translational
cancer research.”
New Knowledge
“The growth of our science and education will be enriched by
new knowledge of our universe and environment, by new
techniques of learning and mapping and observation, by new
tools and computers for industry, medicine, the home as well as
the school.”
So said President John Kennedy in a 1962 speech on
the nation’s commitment to explore space—and so could
be said of modern science’s charge to reduce cancer’s
deadly toll. During the next decade, PennVet’s brightest
researchers may help uncover “new knowledge” that will
allow doctors to detect and block many cancers at the ear-
liest stages. It may very well be that our pets will be can-
cer-free before we are, through basic studies and clinical
trials—yet one more contribution animals would make to
the quality of our lives.
